apomorphine has been researched along with Neurodegenerative Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Abd-Elrahman, KS; Bureau, SC; Derksen, A; Dwyer, Z; Farmer, K; Ferguson, SSG; Fortin, T; Hayley, S; Prowse, NA; Rowe, EM; Rudyk, CA; Thompson, AM | 1 |
| Babayan-Tazehkand, A; Haghdoost-Yazdi, H; Rastgoo, N; Sarbazi-Golezari, A; Sarookhani, MR | 1 |
| Cao, G; Chen, J; Chu, CT; Gao, Y; Greenamyre, JT; Hastings, T; Hu, X; Signore, A; Weng, Z; Zhang, L; Zhu, J | 1 |
| Fleckenstein, AE; Hanson, GR; Truong, JG | 1 |
| Hara, H | 1 |
| Gassen, M; Gross, A; Youdim, MB | 1 |
2 review(s) available for apomorphine and Neurodegenerative Diseases
| Article | Year |
|---|---|
[Molecular mechanism of neuroprotective drugs against oxidative stress-induced neuronal cell death].
Topics: Antioxidants; Apomorphine; Cell Death; Dopamine Agonists; Free Radical Scavengers; Humans; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; NF-E2-Related Factor 2; Oxidative Stress; Response Elements | 2007 |
Apomorphine, a dopamine receptor agonist with remarkable antioxidant and cytoprotective properties.
Topics: Animals; Antioxidants; Apomorphine; Dopamine Agonists; Humans; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Reactive Oxygen Species | 1999 |
4 other study(ies) available for apomorphine and Neurodegenerative Diseases
| Article | Year |
|---|---|
mGluR5 Allosteric Modulation Promotes Neurorecovery in a 6-OHDA-Toxicant Model of Parkinson's Disease.
Topics: Animals; Apomorphine; Disease Models, Animal; Dopaminergic Neurons; Male; Mice; Neurodegenerative Diseases; Oxidopamine; Parkinson Disease; Receptor, Metabotropic Glutamate 5 | 2020 |
Involvement of adenosine triphosphate-sensitive potassium channels in the neuroprotective activity of hydrogen sulfide in the 6-hydroxydopamine-induced animal model of Parkinson's disease.
Topics: Adenosine Triphosphate; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agonists; Hydrogen Sulfide; KATP Channels; Male; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Potassium Channels; Rats; Rats, Wistar; Substantia Nigra | 2018 |
Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Animals; Apomorphine; Brain; Cell Differentiation; Cell Line, Tumor; Cell Survival; Cytochromes; Disease Models, Animal; Dopamine; Enzyme Inhibitors; Female; Gene Expression Regulation; Green Fluorescent Proteins; Humans; Indoles; Male; MAP Kinase Kinase Kinase 5; Mice; Mice, Inbred C57BL; Middle Aged; Motor Activity; Neurodegenerative Diseases; Neuroprostanes; Oxidopamine; Parkinson Disease; Peroxiredoxins; Postmortem Changes; RNA, Small Interfering; Signal Transduction; Thioredoxins | 2011 |
Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration.
Topics: Animals; Apomorphine; Biological Transport; Corpus Striatum; Dopamine; Dopamine Agonists; In Vitro Techniques; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neurodegenerative Diseases; Rats; Rats, Sprague-Dawley; Synaptic Vesicles; Time Factors; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2004 |